These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

185 related items for PubMed ID: 5395883

  • 1. Plasma LATS and thyroid antibody level, and the clinical manifestations of Graves' disease.
    Földes J, Takó J, Bános C, Gesztesi E, Varga I.
    Acta Med Acad Sci Hung; 1969; 26(3):233-43. PubMed ID: 5395883
    [No Abstract] [Full Text] [Related]

  • 2. [Studies on the problem of a relationship between the occurrence of thyroid antibodies and LATS in hyperthyreosis].
    Weissbecker L, Uthgenannt H, Schemmel K, Müller W, Heesen H, Eickenbusch W, Bindeballe W.
    Med Klin; 1966 Dec 30; 61(52):2062-3. PubMed ID: 5999210
    [No Abstract] [Full Text] [Related]

  • 3. LATS and Graves' disease.
    Soloman DH, Chopra IJ.
    Calif Med; 1970 Aug 30; 113(2):50-5. PubMed ID: 5538194
    [No Abstract] [Full Text] [Related]

  • 4. Familial incidence of long-acting thyroid stimulator (LATS) in Graves' disease.
    Bonnyns M, Vanhaelst L.
    Horm Metab Res; 1972 Mar 30; 4(2):132. PubMed ID: 5067566
    [No Abstract] [Full Text] [Related]

  • 5. Absence of allotypic variation in the autoantigen for thyroid stimulating autoantibodies.
    Knight A, Adams DD.
    Clin Exp Immunol; 1983 May 30; 52(2):317-24. PubMed ID: 6134598
    [Abstract] [Full Text] [Related]

  • 6. [Simultaneous study of LATS and antimicrosomial antibodies in untreated Basedow's disease].
    Orgiazzi J, Pousset G, Durand H.
    Presse Med (1893); 1971 May 22; 79(25):1167-8. PubMed ID: 4933634
    [No Abstract] [Full Text] [Related]

  • 7. Absence of thyroid-stimulating antibody and long acting thyroid stimulator in relatives of Graves' disease patients.
    Banovac K, Zakarija M, McKenzie JM, Witte A, Sekso M.
    J Clin Endocrinol Metab; 1981 Sep 22; 53(3):651-3. PubMed ID: 6790561
    [Abstract] [Full Text] [Related]

  • 8. ["Long-acting thyroid stimulator" (LATS) and conventional thyroid antibodies. Comparative studies].
    Depisch D, Höfer R, Schatz H.
    Wien Z Inn Med; 1968 Sep 22; 49(11):418-22. PubMed ID: 5737591
    [No Abstract] [Full Text] [Related]

  • 9. The effect of radioablation of the thyroid gland in Graves' disease with high levels of long-acting thyroid stimulator (LATS).
    Volpé R, Desbarats-Schonbaum ML, Schonbaum E, Row VV, Ezrin C.
    Am J Med; 1969 Feb 22; 46(2):217-26. PubMed ID: 5818477
    [No Abstract] [Full Text] [Related]

  • 10. Heterogeneity of long acting thyroid stimulating (LATS)-activity, thyroglobulin antibodies and thyroid microsomal antibodies.
    Adlkofer F, Schleusener H, Uher L, Ananos A.
    Acta Endocrinol (Copenh); 1973 Jul 22; 73(3):483-8. PubMed ID: 4740843
    [No Abstract] [Full Text] [Related]

  • 11. Studies of an in vitro binding reaction between thyroid microsomes and long acting thyroid stimulator globulin (LATS). I. Development of solid-state competitive binding radioassay methods for measurement of antimicrosomal and antithyroglobuin antibodies.
    Mori T, Fisher J, Kriss JP.
    J Clin Endocrinol Metab; 1970 Aug 22; 31(2):119-33. PubMed ID: 4193195
    [No Abstract] [Full Text] [Related]

  • 12. Autoimmune thyroid disease: an integrated concept of Graves' and Hashimoto's diseases.
    Selenkow HA, Wyman P, Allweiss P.
    Compr Ther; 1984 Apr 22; 10(4):48-56. PubMed ID: 6373115
    [Abstract] [Full Text] [Related]

  • 13. [LATS and Graves' disease].
    Gordon A.
    Harefuah; 1971 May 16; 80(10):569-70. PubMed ID: 5171988
    [No Abstract] [Full Text] [Related]

  • 14. Investigation of endocrine exophthalmos.
    Bowden AN, Ross FC.
    Proc R Soc Med; 1969 Jan 16; 62(1):13-5. PubMed ID: 5818230
    [No Abstract] [Full Text] [Related]

  • 15. Thyroid suppressibility and long-acting thyroid stimulator in thyrotoxicosis.
    Silverstein GE, Burke G.
    Arch Intern Med; 1970 Oct 16; 126(4):615-20. PubMed ID: 4097002
    [No Abstract] [Full Text] [Related]

  • 16. Relationship between the long-acting thyroid stimulator and the thyroid microsomal antibody.
    Bonnyns M, Vanhaelst L.
    J Endocrinol; 1969 Jan 16; 43(1):125-6. PubMed ID: 4886576
    [No Abstract] [Full Text] [Related]

  • 17. [Clinical and hormonal development of a case of malignant exophthalmus after hypophyseal myskiotomy].
    Stoica T, Arseni C, Constantinescu A, Coculescu M, Balmeş E.
    Endocrinologie; 1977 Jan 16; 15(4):283-8. PubMed ID: 579476
    [Abstract] [Full Text] [Related]

  • 18. Transient thyrotoxicosis in an infant delivered to a long-acting thyroid stimulator (LATS)- and LATS protector-negative, thyroid-stimulating antibody-positive woman with Hashimoto's thyroiditis.
    Hoffman WH, Sahasrananan P, Ferandos SS, Burek CL, Rose NR.
    J Clin Endocrinol Metab; 1982 Feb 16; 54(2):354-6. PubMed ID: 6119322
    [Abstract] [Full Text] [Related]

  • 19. What is the antibody specificity of LATS?
    Fagraeus A, Jonsson J, el-Kabir DJ.
    J Clin Endocrinol Metab; 1970 Oct 16; 31(4):445-7. PubMed ID: 4916544
    [No Abstract] [Full Text] [Related]

  • 20. LATS in Graves' disease.
    McKenzie JM, Zakarija M.
    Recent Prog Horm Res; 1976 Oct 16; 33():29-57. PubMed ID: 198858
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 10.